On October 4, 2024 Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, reported that it will present three programs at the 2024 Society of Immunology in Cancer Annual Meeting (SITC 2024) to be held in Houston from November 6-10, 2024 (Press release, Antengene, OCT 4, 2024, View Source [SID1234647039]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of Poster Presentations:

ATG-201 (CD19 x CD3 T-cell Engager)
Title: ATG-201, a novel "2+1" CD19-targeted T-cell Engager (TCE) for the treatment of B cell malignancies and B cell related autoimmune diseases
Abstract Number: 1067
Poster Abstract Presentation at the SITC (Free SITC Whitepaper) Immune Engineering Workshop
Date: November 7, 2024
Time: 3:10 PM – 5:00 PM (Central Standard Time)
5:10 AM – 7:00 AM, Nov 8, 2024 (Beijing Time)
Poster Presentation at the SITC (Free SITC Whitepaper) 39th Annual Meeting
Date: November 8, 2024
Time: 9:00 AM – 7:00 PM (Central Standard Time)
11:00 PM, Nov 8 – 9:00 AM, Nov 9, 2024 (Beijing Time)

ATG-107 (FLT3 x CD3 T-cell Engager)
Title: ATG-107, a novel "2+1" CD3-based T-cell Engager (TCE) targeting FLT3, demonstrates potent preclinical efficacy for the treatment of AML
Abstract Number: 1068
Poster Abstract Presentation at the SITC (Free SITC Whitepaper) Immune Engineering Workshop
Date: November 7, 2024
Time: 3:10 PM – 5:00 PM (Central Standard Time)
5:10 AM – 7:00 AM, Nov 8, 2024 (Beijing Time)
Poster Presentation at the SITC (Free SITC Whitepaper) 39th Annual Meeting
Date: November 9, 2024
Time: 9:00 AM – 8:30 PM (Central Standard Time)
11:00 PM, Nov 9 – 10:30 AM, Nov 10, 2024 (Beijing Time)

ATG-106 (CDH6 x CD3 T-cell Engager)
Title: ATG-106, a novel "2+1" format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy
Abstract Number: 1069
Poster Presentation at the SITC (Free SITC Whitepaper) 39th Annual Meeting
Date: November 8, 2024
Time: 9:00 AM – 7:00 PM (Central Standard Time)
11:00 PM, Nov 8 – 9:00 AM, Nov 9, 2024 (Beijing Time)

About the AnTenGager Platform

The AnTenGager Platform is a proprietary "2+1" T cell engager (TCE) platform developed by Antengene. AnTenGager TCE simultaneously binds to disease-associated antigens (targets) and a unique conformational epitope on CD3 that expressed on T-cells. The bivalent binding to the targets enables detection and depletion of cells with low expression of the targets. In addition, AnTenGager TCE activates T cells in a target-dependent manner so that it demonstrates a lower risk of systemic CD3 activation and cytokine release syndrome (CRS), potentially paving the way for their use in autoimmune diseases, hematological malignancies, and solid tumors.

Our extensive and diverse pipeline features promising TCEs that aim to address unmet medical needs in autoimmune diseases and hematology/oncology, with best-in-class/first-in-class potential. A few of our lead programs in the IND-enabling stage include ATG-201, a CD19 x CD3 TCE for B cell related autoimmune diseases; ATG-102, a LILRB4 x CD3 TCE for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia; ATG-106, a CDH6 x CD3 TCE for ovarian cancer and kidney cancer; ATG-107, a FLT3 x CD3 TCE for AML; and ATG-110, a LY6G6D x CD3 TCE for microsatellite stable (MSS) colorectal cancer.